LMAT

ANALYST NOTE: LeMaitre Vascular, Inc. (LMAT) Date: 2026-06-13 Current Price: $93.95

1. Structural Readiness

• Conservative Entry: Not yet actionable. A conservative entry requires a confirmed breakout above the resistance level defined by the coil's upper boundary.
• Breakout Level: Not yet defined; requires price action to establish the upper boundary of the coil.
• Current Price: $93.95.
• Extension: Not applicable (price has not yet extended from a confirmed breakout).
• ATR Context: Current ATR is 3.4% (productive). This sits within the historical "sweet spot" (4–6% is ideal, but 3.4% indicates manageable volatility for sizing, well below the "extreme" >8% risk zone).

2. Thesis Layer

• Thesis Classification: Tactical / Setup-Led.
• Macro Thesis: There is no named secular thesis attached to this specific setup at this date. The investment case is not driven by a broad macro narrative (e.g., "aging population" or "diabetes epidemic") acting as the primary catalyst, but rather by the company's specific operational execution and the technical setup quality.
• Judgment Criteria: The conviction must be derived strictly from the quality of the technical structure (the forming coil) and the strength of the underlying business fundamentals (revenue growth, guidance, product approvals) as reported by management. Do not invent a macro thesis to justify the trade.

3. Business Fundamentals

LeMaitre Vascular, Inc. is a global provider of medical devices and human tissue cryopreservation services, primarily serving vascular surgeons treating peripheral vascular disease (PVD), end-stage renal disease, and cardiovascular disease.

• Product Portfolio: The company offers a diverse range of devices including anastomotic clips, biologic and synthetic vascular grafts, carotid shunts, embolectomy catheters, and valvulotomes. Biologics (allografts) represented 53% of worldwide sales in Q1 2026, a consistent trend from 51% in 2023.
• Revenue Performance: In Q1 2026, net sales were $66.6 million, up from $59.9 million in the prior year period. Specific product categories posted record sales: Grafts (+20%), Valvulotomes (+15%), and Carotid Shunts (+11%). Worldwide Artegraft sales grew 36% in Q1.
• Management Guidance & Expectations:
• Revenue: Management affirmed full-year 2026 revenue guidance of $280 million, representing 12% organic growth.
• International Expansion (Artegraft): Q1 2026 international Artegraft sales were $2.1 million. Management expects 2026 sales to reach $10 million (vs. $4 million in 2025).
• Regulatory Milestones: Health Canada approved Artegraft; launch is planned for H2 2026 pending packaging validations. Additional approvals for Korea, Brazil, Vietnam, and India are expected in 2027. Filings for the U.S. and Europe are planned for H2 2026, with first sales of longer artegrafts potentially starting in H2 2027.
• Operational Transition: The company is transitioning allograft tissue processing from Fox River Grove to Burlington, expected to be substantially complete by the end of 2026.
• Capital Allocation:
• Buyback: On February 19, 2026, the Board authorized a $100 million stock repurchase program through February 18, 2027.
• Dividend: A quarterly cash dividend of $0.25 per share was approved on April 28, 2026, payable June 4, 2026.

4. Archetype and Conviction

• Archetype: Quality Compounder.
• Fit: The company demonstrates consistent double-digit organic growth (12% guidance), record sales across core categories, and a strategic shift toward higher-margin biologics (53% of sales). The capital allocation (buybacks + dividend) and disciplined international expansion align with a compounder profile.
• Valuation Context: The financial spine indicates a forward consensus EPS of $3.00 for FY1 and $3.26 for FY2. At a current price of $93.95, the stock trades at approximately 31x FY1 EPS. This valuation reflects the high growth expectations (12% organic) and the premium nature of the biologic portfolio.
• Conviction Stack:
• Thesis Strength: Moderate (Tactical, no macro tailwind).
• Evidence Quality: High (Strong Q1 results, clear guidance, specific regulatory milestones).
• Structural Quality: Moderate (ATR is healthy at 3.4%, but the setup is "forming," not "confirmed").
• Rerating Potential: Dependent on the successful H2 2026 launch in Canada and the confirmation of the $10M Artegraft sales target.

5. Invalidations, Strengtheners, and Gaps

• Strengtheners: A confirmed breakout above the coil's resistance level (price action) combined with positive commentary on the H2 2026 Artegraft launch progress would strengthen the case.
• Gaps in Evidence:
• Specific Breakout Level: The exact price level for the breakout (resistance) is not provided in the data, only the current price and ATR.
• Margin Details: While revenue growth is clear, specific margin expansion data for the new Artegraft products is not detailed in the provided excerpts.
• Competitive Landscape: No specific data on competitive pressure in the PVD market is provided beyond the $9B market size estimate.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Q1 sales up 11% with record category performance; Management affirmed $280M FY26 guidance with 12% organic growth; Artegraft sales grew 36% in Q1 with $10M 2026 target; $100M buyback authorized. Key risks: Setup is "forming" not "confirmed" (breakout not fired); Regulatory delays in H2 2026 Canadian launch could impact Artegraft trajectory; High valuation multiple (31x FY1) leaves little room for guidance miss; Transition of tissue processing facility may cause operational friction. Sizing hint: Position size should be reduced relative to a confirmed breakout setup due to the "forming" state; use ATR of 3.4% for tight stop placement. Expected path: Price consolidates near current levels while management executes H2 2026 Canadian launch; a breakout above resistance would confirm the setup and drive re-rating. Expected horizon: 3 to 6 months to see breakout confirmation or setup invalidation.